Chairpersons :

R. Gopal, Manohar Chari, N. Sudhakar

Reviewer :

Bharat Bhosale

1. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for

metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, doubleblind,

placebo-controlled, phase 2 trial

Author: Kim SB

Citation: Lancet Oncol. 2017 Oct;18(10):1360-1372

2. Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate, as

?3rd-line therapeutic option for patients with relapsed/refractory metastatic Triple-

Negative Breast Cancer (mTNBC): Efficacy results

Author: Bardia A.

Citation: SABCS ABSTRACT GS1-07